Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This was an open-label, multi-center, randomized phase 2 study. This is a two-stage design.In
the first stage, two dose groups were set up, the 100 mg bid dose group and the 200 mg qd
dose group, which were randomized at 1:1, with 50 subjects in each group, and a total of 100
cases in the two groups. In the second stage, approximately 36 subjects were added to the
randomized group.